Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Derma

americanpharmaceuticacreviewSeptember 18, 2017

Tag: Baricitinib , Phase 2 Study , Moderate-to-Severe Atopic Dermatitis

PharmaSources Customer Service